Skip to main content
AAN.com

Abstract

Objective:

Cerebral microbleeds are frequently found in the general elderly population and may reflect underlying vascular disease, but their role in cognitive function is unknown.

Methods:

We investigated the association between cerebral microbleeds and performance in multiple cognitive domains in 3,979 persons without dementia (mean age, 60.3 years). Mini-Mental State Examination (MMSE) score and neuropsychological tests were used to assess global cognition and the following cognitive domains: memory, information processing speed, executive function, and motor speed. We used number of microbleeds as continuous variable, and additionally distinguished between persons with no microbleeds, 1 microbleed, 2–4 microbleeds, and ≥5 microbleeds. The association of microbleeds with different cognitive domains was estimated using linear regression models. Additional adjustments were made for vascular risk factors, brain atrophy, and other imaging markers of cerebral small vessel disease. We stratified analyses by location of microbleeds.

Results:

A higher number of microbleeds was associated with lower MMSE score and worse performance on tests of information processing speed and motor speed. When analyzed per category, presence of 5 or more microbleeds was associated with worse performance in all cognitive domains, except memory. These associations were most robust in participants with strictly lobar microbleeds, whereas after additional adjustments associations disappeared for deep or infratentorial microbleeds.

Conclusions:

Presence of numerous microbleeds, especially in a strictly lobar location, is associated with worse performance on tests measuring cognitive function, even after adjustments for vascular risk factors and other imaging markers of small vessel disease. These results suggest an independent role for microbleed-associated vasculopathy in cognitive impairment.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (table_e-1.docx)

Study Funding

The Rotterdam Study is supported by the Erasmus MC University Medical Center and Erasmus University Rotterdam, the Netherlands Organization for Scientific Research (NWO), the Netherlands Organization for Health Research and Development (ZonMW), the Research Institute for Diseases in the Elderly (RIDE), the Netherlands Genomics Initiative, the Ministry of Education, Culture and Science, the Ministry of Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. Dr. Meike W. Vernooij was supported by a grant from the Alzheimer's Association (NIRG-09-13168). This study was also supported by the Netherlands Organization for Scientific Research (NWO) grants 948-00-010 and 918-46-615 and an Erasmus MC grant for translational research. The funding sources had no role in the design or conduct of the study, data collection, data analysis, data interpretation, or in writing or approval of this report.

REFERENCES

1.
Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000;21:153–160.
2.
de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002;33:1152–1162.
3.
Prins ND, van Dijk EJ, den Heijer T, et al. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 2005;128:2034–2041.
4.
Cordonnier C, van der Flier WM, Sluimer JD, Leys D, Barkhof F, Scheltens P. Prevalence and severity of microbleeds in a memory clinic setting. Neurology 2006;66:1356–1360.
5.
Hanyu H, Tanaka Y, Shimizu S, Takasaki M, Abe K. Cerebral microbleeds in Alzheimer's disease. J Neurol 2003;250:1496–1497.
6.
Vernooij MW, van der Lugt A, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology 2008;70:1208–1214.
7.
Werring DJ, Gregoire SM, Cipolotti L. Cerebral microbleeds and vascular cognitive impairment. J Neurol Sci 2010;299:131–135.
8.
Poels MM, Vernooij MW, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam Scan Study. Stroke 2010;41:S103–S106.
9.
Seo SW, Hwa Lee B, Kim EJ, et al. Clinical significance of microbleeds in subcortical vascular dementia. Stroke 2007;38:1949–1951.
10.
Pettersen JA, Sathiyamoorthy G, Gao FQ, et al. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook Dementia Study. Arch Neurol 2008;65:790–795.
11.
Goos JD, Kester MI, Barkhof F, et al. Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke 2009;40:3455–3460.
12.
Takashima Y, Mori T, Hashimoto M, et al. Clinical correlating factors and cognitive function in community-dwelling healthy subjects with cerebral microbleeds. J Stroke Cerebrovasc Dis 2011;20:105–110.
13.
Yakushiji Y, Nishiyama M, Yakushiji S, et al. Brain microbleeds and global cognitive function in adults without neurological disorder. Stroke 2008;39:3323–3328.
14.
Qiu C, Cotch MF, Sigurdsson S, et al. Cerebral microbleeds, retinopathy, and dementia: the AGES-Reykjavik study. Neurology 2010;75:2221–2228.
15.
Hofman A, Breteler MM, van Duijn CM, et al. The Rotterdam study: 2010 objectives and design update. Eur J Epidemiol 2009;24:553–572.
16.
Vernooij MW, Ikram MA, Wielopolski PA, Krestin GP, Breteler MM, van der Lugt A. Cerebral microbleeds: accelerated 3D T2*-weighted GRE MR imaging versus conventional 2D T2*-weighted GRE MR imaging for detection. Radiology 2008;248:272–277.
17.
Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009;8:165–174.
18.
Ikram MA, Vrooman HA, Vernooij MW, et al. Brain tissue volumes in the general elderly population: The Rotterdam Scan study. Neurobiol Aging 2008;29:882–890.
19.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
20.
Bleecker ML, Bolla-Wilson K, Agnew J, Meyers DA. Age-related sex differences in verbal memory. J Clin Psychol 1988;44:403–411.
21.
Golden CJ. Identification of brain disorders by the Stroop color and word test. J Clin Psychol 1976;32:654–658.
22.
Smith A. The symbol digit modalities test: a neuropsychological test for economic screening of learning and other cerebral disorders. Learning Disord 1968;3:83–91.
23.
Desrosiers J, Hebert R, Bravo G, Dutil E. The Purdue Pegboard Test: normative data for people aged 60 and over. Disabil Rehabil 1995;17:217–224.
24.
Welsh KA, Butters N, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part V: a normative study of the neuropsychological battery. Neurology 1994;44:609–614.
25.
Vernooij MW, Ikram MA, Vrooman HA, et al. White matter microstructural integrity and cognitive function in a general elderly population. Arch Gen Psychiatry 2009;66:545–553.
26.
Statistics NCBo. Standard Classification of Education soi-1978. Statistics NCBo, ed. Voorburg; 1987.
27.
Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158–1159.
28.
Biffi A, Halpin A, Towfighi A, et al. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology 2010;75:693–698.
29.
Soo YO, Yang SR, Lam WW, et al. Risk vs benefit of anti-thrombotic therapy in ischaemic stroke patients with cerebral microbleeds. J Neurol 2008;255:1679–1686.
30.
Werring DJ, Frazer DW, Coward LJ, et al. Cognitive dysfunction in patients with cerebral microbleeds on T2*-weighted gradient-echo MRI. Brain 2004;127:2265–2275.
31.
Savitz J, Solms M, Ramesar R. Apolipoprotein E variants and cognition in healthy individuals: a critical opinion. Brain Res Rev 2006;51:125–135.
32.
Greenberg SM, Eng JA, Ning M, Smith EE, Rosand J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke 2004;35:1415–1420.
33.
Gilbert JJ, Vinters HV. Cerebral amyloid angiopathy: incidence and complications in the aging brain: I: cerebral hemorrhage. Stroke 1983;14:915–923.
34.
Filley CM. The behavioral neurology of cerebral white matter. Neurology 1998;50:1535–1540.
35.
Seghier ML, Kolanko MA, Leff AP, Jager HR, Gregoire SM, Werring DJ. Microbleed detection using automated segmentation (MIDAS): a new method applicable to standard clinical MR images. PLoS One 2011;6:e17547.
36.
Dierksen GA, Skehan ME, Khan MA, et al. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol 2010;68:545–548.
37.
Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 2002;58:1629–1634.
38.
Fernando MS, Ince PG, Function MRCC, Ageing Neuropathology Study Group. Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol Sci 2004;226:13–17.
39.
Arvanitakis Z, Leurgans SE, Wang Z, Wilson RS, Bennett DA, Schneider JA. Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann Neurol 2011;69:320–327.
40.
Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer's disease: innocent observation or key player? Brain 2011;134:335–344.

Information & Authors

Information

Published In

Neurology®
Volume 78Number 5January 31, 2012
Pages: 326-333
PubMed: 22262748

Publication History

Received: June 23, 2011
Accepted: September 23, 2011
Published online: January 18, 2012
Published in print: January 31, 2012

Permissions

Request permissions for this article.

Disclosure

Dr. Poels reports no disclosures. Dr. Ikram has received research support from the Nederlandse Hartstichting and the Internationaal Parkinson Fonds and serves on the editorial board for Neuroepidemiology. Dr. Van der Lugt receives research support from Bayer Schering Pharma, the Dutch Heart Foundation, and the Alzheimer's Association USA and has served as a consultant for GE Healthcare. Dr. Hofman has received funding for travel from GlaxoSmithKline; serves as Editor-in-Chief for the European Journal of Epidemiology; receives publishing royalties for Grondslagen der epidemiologie (Elsevier, 2008), Klinische epidemiologie (Elsevier, 2000), and Investigating Neurological Disease (Cambridge University Press, 1996); and receives research support from the Netherlands Genomics Initiative for the Rotterdam Study and from the Ministry of Health for the Generation R study. Dr. Niessen serves as an Associate Editor for IEEE Transactions on Medical Imaging and Associate Editor for Medical Image Analysis. Dr. Krestin serves on the editorial boards of MagMa, Abdominal Imaging, European Radiology, Investigative Radiology, Radiologica Medica, Contrast Media, and Molecular Imaging; serves as a consultant for GE Healthcare; has received honoraria from Bayer Schering Pharma, GE Healthcare, and Siemens Medical Solutions; and receives/has received research support from Bayer Schering Pharma, GE Healthcare, Philips Healthcare, Siemens Medical Solutions, the European Commission FP6 and FP7, the Dutch Science Organization, Cancer Foundation Netherlands, and Heart Foundation Netherlands. Dr. Breteler serves on editorial advisory boards for Neuroepidemiology, Alzheimer's & Dementia, and Stroke; and receives research support from Pfizer Inc, the Netherlands Organization for Scientific Research, the Alzheimer's Association USA, the NIH, the Internationale Stichting Alzheimer Onderzoek (ISAO), the Dutch Cancer Society, the Dutch Parkinsonfonds, and the Netherlands Brain Foundation. Dr. Vernooij receives research support from the Alzheimer's Association.

Authors

Affiliations & Disclosures

M.M.F. Poels, MD
From the Department of Epidemiology (M.M.F.P., M.A.I., A.H., M.M.B.B., M.W.V.), Department of Radiology (M.M.F.P., M.A.I., A.v.d.L., G.P.K., M.W.V.), and Biomedical Imaging Group Rotterdam, Departments of Radiology & Medical Informatics (W.J.N.), Erasmus MC University Medical Center, Rotterdam; and Imaging Science & Technology (W.J.N.), Faculty of Applied Sciences, Delft University of Technology, Delft, the Netherlands.
M.A. Ikram, MD, PhD
From the Department of Epidemiology (M.M.F.P., M.A.I., A.H., M.M.B.B., M.W.V.), Department of Radiology (M.M.F.P., M.A.I., A.v.d.L., G.P.K., M.W.V.), and Biomedical Imaging Group Rotterdam, Departments of Radiology & Medical Informatics (W.J.N.), Erasmus MC University Medical Center, Rotterdam; and Imaging Science & Technology (W.J.N.), Faculty of Applied Sciences, Delft University of Technology, Delft, the Netherlands.
A. van der Lugt, MD, PhD
From the Department of Epidemiology (M.M.F.P., M.A.I., A.H., M.M.B.B., M.W.V.), Department of Radiology (M.M.F.P., M.A.I., A.v.d.L., G.P.K., M.W.V.), and Biomedical Imaging Group Rotterdam, Departments of Radiology & Medical Informatics (W.J.N.), Erasmus MC University Medical Center, Rotterdam; and Imaging Science & Technology (W.J.N.), Faculty of Applied Sciences, Delft University of Technology, Delft, the Netherlands.
A. Hofman, MD, PhD
From the Department of Epidemiology (M.M.F.P., M.A.I., A.H., M.M.B.B., M.W.V.), Department of Radiology (M.M.F.P., M.A.I., A.v.d.L., G.P.K., M.W.V.), and Biomedical Imaging Group Rotterdam, Departments of Radiology & Medical Informatics (W.J.N.), Erasmus MC University Medical Center, Rotterdam; and Imaging Science & Technology (W.J.N.), Faculty of Applied Sciences, Delft University of Technology, Delft, the Netherlands.
W.J. Niessen, PhD
From the Department of Epidemiology (M.M.F.P., M.A.I., A.H., M.M.B.B., M.W.V.), Department of Radiology (M.M.F.P., M.A.I., A.v.d.L., G.P.K., M.W.V.), and Biomedical Imaging Group Rotterdam, Departments of Radiology & Medical Informatics (W.J.N.), Erasmus MC University Medical Center, Rotterdam; and Imaging Science & Technology (W.J.N.), Faculty of Applied Sciences, Delft University of Technology, Delft, the Netherlands.
G.P. Krestin, MD, PhD
From the Department of Epidemiology (M.M.F.P., M.A.I., A.H., M.M.B.B., M.W.V.), Department of Radiology (M.M.F.P., M.A.I., A.v.d.L., G.P.K., M.W.V.), and Biomedical Imaging Group Rotterdam, Departments of Radiology & Medical Informatics (W.J.N.), Erasmus MC University Medical Center, Rotterdam; and Imaging Science & Technology (W.J.N.), Faculty of Applied Sciences, Delft University of Technology, Delft, the Netherlands.
M.M.B. Breteler, MD, PhD
From the Department of Epidemiology (M.M.F.P., M.A.I., A.H., M.M.B.B., M.W.V.), Department of Radiology (M.M.F.P., M.A.I., A.v.d.L., G.P.K., M.W.V.), and Biomedical Imaging Group Rotterdam, Departments of Radiology & Medical Informatics (W.J.N.), Erasmus MC University Medical Center, Rotterdam; and Imaging Science & Technology (W.J.N.), Faculty of Applied Sciences, Delft University of Technology, Delft, the Netherlands.
M.W. Vernooij, MD, PhD
From the Department of Epidemiology (M.M.F.P., M.A.I., A.H., M.M.B.B., M.W.V.), Department of Radiology (M.M.F.P., M.A.I., A.v.d.L., G.P.K., M.W.V.), and Biomedical Imaging Group Rotterdam, Departments of Radiology & Medical Informatics (W.J.N.), Erasmus MC University Medical Center, Rotterdam; and Imaging Science & Technology (W.J.N.), Faculty of Applied Sciences, Delft University of Technology, Delft, the Netherlands.

Notes

Study funding: Funding information is provided at the end of the article.
Correspondence & reprint requests to Dr. Vernooij: [email protected]

Author Contributions

Dr. Poels: drafting the manuscript for content, analysis or interpretation of data, acquisition of data, statistical analysis. Dr. Ikram: revising the manuscript for content, acquisition of data. Dr. van der Lugt: revising the manuscript for content. Dr. Hofman: revising the manuscript for content, study concept or design, obtaining funding. Dr. Niessen: revising the manuscript for content. Dr. Krestin: revising the manuscript for content, obtaining funding. Dr. Breteler: revising the manuscript for content, study concept or design, obtaining funding. Dr. Vernooij: revising the manuscript for content, analysis or interpretation of data, acquisition of data, study supervision or coordination. Dr. Poels and Dr. Vernooij had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the statistical data analysis.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Association of Atrial Fibrillation and Cognitive Dysfunction: A Comprehensive Narrative Review of Current Understanding and Recent Updates, Journal of Clinical Medicine, 13, 18, (5581), (2024).https://doi.org/10.3390/jcm13185581
    Crossref
  2. Cerebral Microbleeds Associate with Brain Endothelial Cell Activation-Dysfunction and Blood–Brain Barrier Dysfunction/Disruption with Increased Risk of Hemorrhagic and Ischemic Stroke, Biomedicines, 12, 7, (1463), (2024).https://doi.org/10.3390/biomedicines12071463
    Crossref
  3. Preliminary evidence of high prevalence of cerebral microbleeds in astronauts with spaceflight experience, Frontiers in Physiology, 15, (2024).https://doi.org/10.3389/fphys.2024.1360353
    Crossref
  4. IGF1R deficiency in vascular smooth muscle cells impairs myogenic autoregulation and cognition in mice, Frontiers in Aging Neuroscience, 16, (2024).https://doi.org/10.3389/fnagi.2024.1320808
    Crossref
  5. Diagnostic Performance Using a Combination of MRI Findings for Evaluating Cognitive Decline, Journal of the Korean Society of Radiology, 85, 1, (184), (2024).https://doi.org/10.3348/jksr.2023.0065
    Crossref
  6. Association Between Small Vessel Disease and Financial Capacity: A Study Based on Cognitively Normal Older Adults, Journal of Alzheimer's Disease, 98, 3, (897-906), (2024).https://doi.org/10.3233/JAD-231089
    Crossref
  7. Using Neuroimaging to Study Cerebral Amyloid Angiopathy and Its Relationship to Alzheimer’s Disease, Journal of Alzheimer's Disease, 97, 4, (1479-1502), (2024).https://doi.org/10.3233/JAD-230553
    Crossref
  8. Stroke and Vascular Cognitive Impairment: The Role of Intestinal Microbiota Metabolite TMAO, CNS & Neurological Disorders - Drug Targets, 23, 1, (102-121), (2024).https://doi.org/10.2174/1871527322666230203140805
    Crossref
  9. The presence of circulating human apolipoprotein J reduces the occurrence of cerebral microbleeds in a transgenic mouse model with cerebral amyloid angiopathy, Alzheimer's Research & Therapy, 16, 1, (2024).https://doi.org/10.1186/s13195-024-01541-5
    Crossref
  10. Basic Mechanisms of Brain Injury and Cognitive Decline in Hypertension, Hypertension, 81, 1, (34-44), (2024).https://doi.org/10.1161/HYPERTENSIONAHA.123.19939
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share